[Remote] Director, Global Scientific Publications (East Coast Based Candidates Only) at Axsome Therapeutics Inc

United States

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, Medical ResearchIndustries

Requirements

Candidates should possess a Bachelor’s degree in a scientific discipline, such as Biology, Chemistry, or Pharmacology, and ideally hold a Master’s or Doctoral degree. They should have at least 8 years of experience in scientific publications, with a strong understanding of the pharmaceutical industry and regulatory guidelines. Experience managing teams and collaborating with cross-functional teams is also required.

Responsibilities

The Director, Global Scientific Publications will oversee the management and delivery of scientific publications in alignment with brand publication plans, collaborating with internal and external stakeholders to review and provide scientific consultation regarding publication-related material. They will strategize and identify publication opportunities, coordinate publication activities with vendors and internal teams, monitor publication requirements for congresses and journals, define operational milestones, and ensure adherence to regulatory requirements and SOPs. The role also involves acting as a liaison at meetings, submitting abstracts and clinical papers, attending scientific congresses, applying scientific acumen, and documenting publication processes through PubSTRAT.

Skills

Scientific Publications

Scientific Content Development

Publication Management

Stakeholder Collaboration

Regulatory Compliance

Medical Affairs

Vendor Management

Cross-functional Communication

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters

2012Year Founded

$430.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Performance Bonus

Company Equity

Risks

Increased competition from companies like Compass Pathways in the CNS market.

Potential delays in AXS-07 launch amid growing market anticipation.

Departure of key personnel like Lori Englebert may impact strategic direction.

Differentiation

Axsome focuses on CNS disorders with limited current treatment options.

AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.

Axsome's balanced portfolio includes both clinical and research stage products.

Upsides

FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.

Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.

Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

Land your dream remote job 3x faster with AI

Try Jobo Free